胸腺肽联合参麦辅助治疗慢性阻塞性肺病急性加重期的疗效及安全性(1)
[摘要] 目的 分析胸腺肽联合参麦辅助治疗慢性阻塞性肺病急性加重期的疗效及安全性。 方法 整群选取该院2014年1月—2015年6月收治的100例慢性阻塞性肺病急性加重期患者，随机分为两组。常规组患者接受胸腺肽治疗，干预组患者在此基础上辅以参麦治疗。观察两组氧气分压、二氧化碳分压和肺功能。结果 治疗后所有患者氧气分压和二氧化碳分压均改善，且干预组改善水平显著优于常规组(P<0.05)；治疗后所有患者肺功能指标均较治疗前提高，且干预组FEV1、FVC、VC、PEF指标水平显著高于常规组(P<0.05)。两组安全性相似(P>0.05)。 结论 胸腺肽联合参麦治疗慢性阻塞性肺病急性加重期效果确切。
[关键词] 胸腺肽；参麦；慢阻肺
[中图分类号] R473.73 [文献标识码] A [文章编号] 1674-0742(2015)11(b)-0148-02
[Abstract] Objective To analyze the curative effect and safety of thymic peptide assisted with shenmai injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods 100 patients suffering from acute exacerbation of chronic obstructive pulmonary disease from January 2014 and June 2015 were randomly divided into two groups. Patients in the conventional group were treated with thymic peptide， while those in the intervention group were treated with thymic peptide assisted with shenmai injection. The oxygen partial pressure， carbon dioxide partial pressure and pulmonary function of the two groups were observed. Results After treatment， all the patients got improvement in terms of oxygen partial pressure， carbon dioxide partial pressure， and the improvement of the intervention group was better than that in the conventional group，(P<0.05)； all the patients got improvement in pulmonary function after treatment， what's more， the indicators including FEV1， FVC， VC， PEF were all higher in the intervention group than in the conventional group，(P<0.05). No statistically significant difference can be found in safety of the treatment between the two groups， (P>0.05). Conclusion The curative effect of thymic peptide assisted with shenmai injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease is evident.
[Key words] Thymosin； Shenmai； Chronic obstructive pulmonary disease
慢阻肺属呼吸系统疾病，临床发病率较高。近些年来，随着环境污染的加重，慢阻肺的发病率也逐渐显现明显的上升趋势[1]。目前，慢阻肺急性加重期的治疗方法主要是呼吸机辅助通气治疗、平喘解痉、抗炎吸氧和呼吸兴奋剂等。该研究分析了胸腺肽联合参麦辅助治疗慢性阻塞性肺病急性加重期的疗效及安全性，现报道如下。
1 资料与方法
1.1 一般资料
整群选取2014年1月—2015年6月该院收治的100例慢性阻塞性肺病急性加重期患者。随机分组，常规组50例，其中男26例，女24例；体重49～79 kg，平均体重(63.83±12.62)kg；年龄42～78岁，平均年龄(62.77±8.35)岁；病程1～14年，平均病程(4.55±1.52)年。干预组50例，其中男27例，女23例；体重48～81 kg，平均体重(63.34±12.28)kg；年龄40～77岁，平均年龄(62.27±8.73)岁；病程1～15年，平均病程(4.96±1.62)年。两组患者上述各方面病历资料差异无统计学意义(P>0.05)，具有可比性。
1.2 方法
两组均给予常规治疗，主要包括抗感染、吸氧、利尿、扩张血管、强心以及纠正电解质紊乱及酸碱平衡紊乱等对症治疗[2]。
常规组患者接受胸腺肽治疗(商品名：注射用胸腺肽；国药准字H61023596；西安迪赛生物药业有限责任公司)规格：50 mg。静脉滴注：100 mg/次，1次/d。 (毛静)
[关键词] 胸腺肽；参麦；慢阻肺
[中图分类号] R473.73 [文献标识码] A [文章编号] 1674-0742(2015)11(b)-0148-02
[Abstract] Objective To analyze the curative effect and safety of thymic peptide assisted with shenmai injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods 100 patients suffering from acute exacerbation of chronic obstructive pulmonary disease from January 2014 and June 2015 were randomly divided into two groups. Patients in the conventional group were treated with thymic peptide， while those in the intervention group were treated with thymic peptide assisted with shenmai injection. The oxygen partial pressure， carbon dioxide partial pressure and pulmonary function of the two groups were observed. Results After treatment， all the patients got improvement in terms of oxygen partial pressure， carbon dioxide partial pressure， and the improvement of the intervention group was better than that in the conventional group，(P<0.05)； all the patients got improvement in pulmonary function after treatment， what's more， the indicators including FEV1， FVC， VC， PEF were all higher in the intervention group than in the conventional group，(P<0.05). No statistically significant difference can be found in safety of the treatment between the two groups， (P>0.05). Conclusion The curative effect of thymic peptide assisted with shenmai injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease is evident.
[Key words] Thymosin； Shenmai； Chronic obstructive pulmonary disease
慢阻肺属呼吸系统疾病，临床发病率较高。近些年来，随着环境污染的加重，慢阻肺的发病率也逐渐显现明显的上升趋势[1]。目前，慢阻肺急性加重期的治疗方法主要是呼吸机辅助通气治疗、平喘解痉、抗炎吸氧和呼吸兴奋剂等。该研究分析了胸腺肽联合参麦辅助治疗慢性阻塞性肺病急性加重期的疗效及安全性，现报道如下。
1 资料与方法
1.1 一般资料
整群选取2014年1月—2015年6月该院收治的100例慢性阻塞性肺病急性加重期患者。随机分组，常规组50例，其中男26例，女24例；体重49～79 kg，平均体重(63.83±12.62)kg；年龄42～78岁，平均年龄(62.77±8.35)岁；病程1～14年，平均病程(4.55±1.52)年。干预组50例，其中男27例，女23例；体重48～81 kg，平均体重(63.34±12.28)kg；年龄40～77岁，平均年龄(62.27±8.73)岁；病程1～15年，平均病程(4.96±1.62)年。两组患者上述各方面病历资料差异无统计学意义(P>0.05)，具有可比性。
1.2 方法
两组均给予常规治疗，主要包括抗感染、吸氧、利尿、扩张血管、强心以及纠正电解质紊乱及酸碱平衡紊乱等对症治疗[2]。
常规组患者接受胸腺肽治疗(商品名：注射用胸腺肽；国药准字H61023596；西安迪赛生物药业有限责任公司)规格：50 mg。静脉滴注：100 mg/次，1次/d。 (毛静)